AC Immune SA (ACIU)
$
1.68
-0.01 (-0.60%)
Key metrics
Financial statements
Free cash flow per share
0.4513
Market cap
137.1 Million
Price to sales ratio
4.8455
Debt to equity
0.0546
Current ratio
1.5329
Income quality
-0.8832
Average inventory
0
ROE
-0.4522
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
The weighted average number of shares outstanding is 99,691,971.00 highlighting the company's shareholder base. The company's stock is identified with the symbol 'ACIU' in the market, reflecting its presence and recognition among investors. The gross profit stands at $27,309,000.00 highlighting the company's profitability from core operations. Additionally, the total costs and expenses for the company are $79,687,000.00 reflecting its overall spending. The net income ratio is -1.86 reflecting the company's profitability margin. AC Immune SA, a clinical-stage biopharmaceutical firm, discovers, designs, and develops medicines and diagnostic products aimed at the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Through its innovative SupraAntigen and Morphomer platforms, the company generates vaccines, antibodies, and small molecules that specifically interact with misfolded proteins found in various neurodegenerative diseases. Among its key developments is Crenezumab, a monoclonal antibody that is currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Furthermore, the company is advancing ACI-24, an anti-Abeta vaccine candidate in Phase II clinical study for AD, which has also completed a Phase Ib clinical study for Down syndrome, along with ACI-35, an anti-Tau vaccine candidate that has finished its Phase Ib clinical study. The stock is affordable at $1.68 suitable for budget-conscious investors looking for potential growth opportunities. However, the stock has a low average trading volume of 166,455.00 indicating lower market activity. With a market capitalization of $166,224,408.00 the company is classified as a small-cap player. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Moreover, it belongs to the Healthcare sector, driving innovation and growth through its range of research and development efforts, including the investigation of Tau aggregation inhibitors for Alzheimer's disease and other NeuroOrphan conditions. The company has also established partnerships and licensing agreements with notable organizations such as Genentech, Inc., Biogen International GmbH, and Eli Lilly and Company, enhancing its strategic position in the market.
Is AC Immune SA (ACIU) a good investment?
Investing in AC Immune SA (ACIU) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is AC Immune SA (ACIU)'s stock forecast?
Analysts predict AC Immune SA stock to fluctuate between $1.43 (low) and $4.98 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is AC Immune SA's market capitalization?
As of 2025-05-28, AC Immune SA's market cap is $166,224,408, based on 98,943,100 outstanding shares.
How does AC Immune SA compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., AC Immune SA has a Lower Market-Cap, indicating a difference in performance.
How can I buy AC Immune SA (ACIU) stock?
To buy AC Immune SA (ACIU) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACIU. Place an order (Market, Limit, etc.).
What is the best time to invest in AC Immune SA?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did AC Immune SA perform in the last earnings report?
Revenue: $27,309,000 | EPS: -$0.51 | Growth: -20.31%.
Where can I find AC Immune SA's investor relations reports?
Visit https://www.acimmune.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for AC Immune SA?
You can explore historical data from here
What is the all-time high and low for AC Immune SA stock?
All-time high: $12.61 (2021-08-31) | All-time low: $1.43 (2025-04-09).
What are the key trends affecting AC Immune SA stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
a month ago
AC Immune (ACIU) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.21 per share a year ago.
globenewswire.com
a month ago
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseases Positive immunogenicity and good safety in interim results for wholly owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in Phase 2 trial in Parkinson's disease (PD) Additional ACI-7104.056 Phase 2 interim results (pharmacodynamics and biomarkers) expected in Q2 2025 Presentations at International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) highlight leadership in active immunotherapy and promising data on early-stage assets Cash resources of CHF 145.7 million as of March 31, 2025 provide funding into Q1 2027 before any potential milestones Lausanne, Switzerland, April 30, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the quarter ended March 31, 2025, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “AC Immune's portfolio of active immunotherapies for precision prevention of neurodegeneration continues to advance in clinical development.
globenewswire.com
2 months ago
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease
globenewswire.com
2 months ago
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company's industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases Multiple presentations at the International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) showcasing the diversity of the company's precision medicine pipeline Lausanne, Switzerland, March 25, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025) taking place in Vienna, Austria, on April 1 – 5, 2025. AC Immune will host an industry symposium highlighting advances in the clinical development of active immunotherapies featuring key opinion leaders, industry experts and AC Immune leadership.
zacks.com
2 months ago
AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, we advise investors to remain on the sidelines for now.
globenewswire.com
3 months ago
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon commercialization ACI-24.060 ABATE Phase 1b/2 trial showed encouraging interim safety and tolerability data in Down syndrome (DS) cohort; further interim results in Alzheimer's disease (AD) and DS expected in 2025 Enrollment progress in JNJ-2056 (ACI-35.030) ReTain Phase 2b trial in preclinical AD patients triggered second milestone payment of CHF 24.6 million; JNJ-2056 granted U.S. FDA Fast Track Designation in AD ACI-7104.056 VacSYn Phase 2 trial demonstrated positive interim safety and immunogenicity results in Parkinson's disease (PD); further interim results in H1 2025 Cash resources of CHF 165.5 million at year end provides funding into Q1 2027, assuming no other milestones Lausanne, Switzerland, March 13, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the full year ended December 31, 2024, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We significantly advanced our leading position in the precision prevention of neurodegenerative diseases in 2024 through strong pipeline progress and the closing of a landmark deal with Takeda.
zacks.com
3 months ago
AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
3 months ago
PFLT, COMM, BGC, NLY and ACIU have been added to the Zacks Rank #1 (Strong Buy) List on March 5, 2025.
zacks.com
4 months ago
The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
zacks.com
4 months ago
ENS, SOPA, MC, SFIX and ACIU have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
See all news
